$2.11
Today
as of Sep 4, 16:50 ET
Last 30 days
Recent Press Releases & News
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Century Therapeutics (IPSC) to Present CNTY-813 Data at Scientific Congresses
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
Overview
52-week range
$0.43
$3.04
64% of range
Avg surprise (last 3)
+137.9%
Avg reaction (last 2)
+2.6%
50% positive
Latest IV / EM
203%
EM ±41.5% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.17 | — | — | — | — | financials |
| Wed May 13, 2026 | Mar/2026 | $-0.11 | $-0.15 | +26.7% | -112.4% | -0.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.40 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.38 | $-0.38 | 0.0% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $0.89 | $-0.31 | +387.1% | — | +5.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.37 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.38 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.45 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.55 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.56 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.53 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $109M | — | $791,000 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-37M | $-24M | — | $-36M | $-35M | $74M | — | $-35M |
| Net income | $-35M | $-22M | — | $-34M | $-33M | $77M | — | $-31M |
| EPS (diluted) | $-0.17 | $-0.11 | — | $-0.40 | $-0.38 | $0.89 | — | $-0.37 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $50M | $51M | $62M | $56M | $57M | $52M | $58M | $53M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $125M | $139M | $121M | $138M | $160M | $170M | $194M | $206M |
| Total assets | $287M | $327M | $224M | $245M | $285M | $316M | $353M | $389M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $55M | $62M | $65M | $68M | $75M | $75M | $192M | $193M |
| Total equity | $232M | $265M | $159M | $176M | $210M | $240M | $161M | $196M |